Emergent BioSolutions Inc

Emergent BioSolutions On Track with Respect to COVID-19 Contractual Commitments; Receives Modified Task Order from the U.S. Department of Health & Human Services to Support the Opportunity for Further Expansion of Manufacturing Capacity for Johnson & Johnson’s COVID-19 Vaccine

04 أبريل 2021 22:09:06 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions Announces Topline Data from NIAID Phase 3 ITAC Trial (INSIGHT-013) Evaluating Immunoglobulins as a Treatment for Hospitalized Patients with COVID-19

02 أبريل 2021 08:00:00 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions to Participate in Investor Conferences

01 مارس 2021 06:30:00 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions Reports Financial Results for Fourth Quarter and Full Year 2020

18 فبراير 2021 16:05:01 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions to Release Fourth Quarter and Full Year 2020 Financial Results and Conduct a Conference Call on February 18, 2021

04 فبراير 2021 06:30:00 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions Announces 2021 Financial Guidance, Provides Preliminary 2020 Results

10 يناير 2021 14:00:00 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions to Participate in Investor Conferences

04 يناير 2021 06:30:00 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions and Mount Sinai Health System Announce Initiation of DOD-Funded Clinical Program to Evaluate COVID-19 Human Hyperimmune Globulin (COVID-HIG) Product Candidate for Prophylaxis

29 ديسمبر 2020 16:05:00 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2020 and Updates Full Year 2020 Guidance

05 نوفمبر 2020 16:05:03 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions to Release Third Quarter 2020 Financial Results and Conduct Conference Call on November 5, 2020

15 أكتوبر 2020 06:30:10 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions’ COVID-19 Human Immune Globulin Product Candidate to be Included in NIH-Sponsored Phase 3 Clinical Trial of Hyperimmune Intravenous Immunoglobulin to Treat COVID-19

08 أكتوبر 2020 16:05:10 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions Teams Up with Boston Red Sox, Cincinnati Reds, Philadelphia Phillies, and MAPDA to Highlight Importance of Overdose Reversal Medicines on International Overdose Awareness Day

31 أغسطس 2020 06:30:10 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions Announces Appointment of Marvin White to the Company’s Board of Directors

26 أغسطس 2020 06:30:10 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions to Participate in Virtual Investor Conferences

18 أغسطس 2020 06:31:56 بحسب Nasdaq GlobeNewswire

UPDATE -- Emergent BioSolutions Announces FDA Approval of NARCAN® (naloxone HCl) Nasal Spray Shelf Life Extension to 36 Months

17 أغسطس 2020 11:54:37 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions Announces FDA Approval of NARCAN® (naloxone HCl) Nasal Spray Shelf Life Extension to 36 Months

17 أغسطس 2020 06:30:10 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions Announces Successful Completion of Offering of 3.875% Senior Unsecured Notes Due 2028

07 أغسطس 2020 16:05:10 بحسب Nasdaq GlobeNewswire

NetDania - New 12 months High: Emergent BioSolutions Inc

06 أغسطس 2020 09:52:18 بحسب NetDania Notify

NetDania - New 12 months High: Emergent BioSolutions Inc

05 أغسطس 2020 09:45:04 بحسب NetDania Notify

Emergent BioSolutions Announces Upsize and Pricing of $450 Million of 3.875% Senior Unsecured Notes Due 2028

04 أغسطس 2020 18:32:02 بحسب Nasdaq GlobeNewswire